ARCH BIOPARTNERS INC (ARCH.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:ARCH - CA03938C1041 - Common Stock
ARCH.CA Key Statistics, Chart & Performance
The current stock price of ARCH.CA is 1.02 CAD. In the past month the price decreased by -13.56%. In the past year, price decreased by -50.24%.
ARCH.CA Latest News, Press Relases and Analysis
ARCH.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| IOT.CA | INNOVOTECH INC | 23 | 11.56M |
Related stock screener links
About ARCH.CA
Company Profile
Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
Company Info
ARCH BIOPARTNERS INC
545 King St W.
TORONTO ONTARIO M5V 1M1 CA
CEO: Richard Muruve
Employees: 0
Phone: 16474287031
ARCH BIOPARTNERS INC / ARCH.CA FAQ
What does ARCH do?
Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.
What is the current price of ARCH stock?
The current stock price of ARCH.CA is 1.02 CAD. The price increased by 3.03% in the last trading session.
Does ARCH BIOPARTNERS INC pay dividends?
ARCH.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARCH stock?
ARCH.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ARCH stock?
ARCH BIOPARTNERS INC (ARCH.CA) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the employee count for ARCH stock?
ARCH BIOPARTNERS INC (ARCH.CA) currently has 0 employees.
Who owns ARCH BIOPARTNERS INC?
You can find the ownership structure of ARCH BIOPARTNERS INC (ARCH.CA) on the Ownership tab.
ARCH.CA Technical Analysis
ARCH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARCH.CA. ARCH.CA may be in some trouble as it scores bad on both profitability and health.
ARCH.CA Financial Highlights
Over the last trailing twelve months ARCH.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 61.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -895.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARCH.CA Forecast & Estimates
7 analysts have analysed ARCH.CA and the average price target is 3.57 CAD. This implies a price increase of 250% is expected in the next year compared to the current price of 1.02.